Cohort study of risk of secondary cancer among patients with primary cutaneous B-cell lymphoma

A retrospective cohort study using the SEER17 database investigated the risk of subsequent primary malignancies among patients with a diagnosis of primary cutaneous B-cell lymphoma (pCBCL). Among 3757 patients with a diagnosis of pCBCL from January 2000 to December 2020, 343 (9.1%) had a second cancer (SIR 1.37; 95% CI, 1.23-1.52). Patients had increased risk of prostate cancer (SIR 1,49; 95% CI, 1.13-1.92), all lymphatic and hematopoietic diseases (4.79; 3.94-5.77), and lymphoma (8.01; 6.46-9.81). Patients with versus without subsequent cancer were frequently of White race and aged 50 to 74 years. Females had shorter latency to secondary cancers compared with males (on average 9.9 versus 12.2 years). The authors conclude that future studies should consider patient factors associated with secondary cancers when developing screening guides.